Canaccord Genuity Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 61.1%

Neg 0% Neu 0% Pos 61.1%

Canaccord Genuity analyst Whitney Ijem initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces Price Target of $35.